Latest Breaking News On - Endocrinology clinical development updates - Page 1 : comparemela.com

29.05.2024 - Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year .

Chau chengExchange commissionNeurology clinical development updatesDue to roivant sciences ltdGeneral clinical development updatesEndocrinology clinical development updatesImmunovant incClinical development updatesThyroid eye diseaseInsulin growth factorFiscal fourth quarter ended marchFiscal year ended marchPrivate securities litigation reform actAnnual reportRoivant sciences